The Specter Of Spin-off Plans Dominates Pfizer Year-end Earnings
This article was originally published in The Pink Sheet Daily
Executive Summary
Although the company beat estimates and executed on an ambitious late-stage pipeline, analysts on Pfizer’s earnings call were focused on palbociclib, Prevnar, and the pharma’s plans for its established products business.
You may also be interested in...
Emerging Markets Earnings Roundup: GSK, AbbVie, Novo Nordisk (Part 5)
GSK reported that China pharmaceutical and vaccines sales were down 29% in Q4 and 18% for full year 2013, but CEO Andrew Witty tried to assure investors that sales are stabilizing. AbbVie chugs along on Humira and Novo Nordisk warns that emerging markets currency volatility may hit launch plans.
Emerging Markets Earnings Roundup: BMS, Pfizer (Part 2)
BMS elaborated on its plans to ease out of the emerging market explosion in demand for diabetes treatments as it moves to develop new therapies in immune-oncology. Pfizer saw China revenues rise smartly in the fourth quarter and Lipitor sales standout in emerging markets.
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.